Day: November 5, 2020

STAMFORD, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle Bulk”, “Eagle” or the “Company”), one of the world’s largest owner-operators within the Supramax / Ultramax drybulk segment, today reported financial results for the three and nine months ended September 30, 2020.Highlights for the Quarter:Revenues, net of $68.2 millionTCE Revenue (1) for the quarter equated to $42.4 millionAchieved TCE (1) of $9,620/day for the quarter versus the Adjusted net BSI (2) at $9,429/day Realized a net loss of $11.2 million, or $1.09 per basic and diluted share Adjusted EBITDA(1) of $11.5 million Completed the 1-for-7 reverse stock split that became effective on September 15, 2020 Reached an agreement to sell the M/V Skua (2003-built Supramax) for a gross price of $5.4 million. Closing is expected to occur...

BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2020 financial results and provided a business update.“We continue to enroll in our ongoing NC318 and NC410 clinical trials. In addition, we are making progress analyzing biomarker data, including Siglec-15 expression in biopsies from the NC318 Phase 2 trial,” said Michael Richman, NextCure’s president and chief executive officer. “We look forward to providing a clinical update and additional biomarker data on the NC318 monotherapy trial by the end of 2020 and remain committed to our goal of developing novel immunomedicines for patients who do not respond...

Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31%SOUTH ORANGE, NJ, Nov. 05, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that Dan D’Agostino was appointed the company’s Chief Financial Officer, effective November 6, 2020. Nephros also announced financial results for the three months ended September 30, 2020.“We have known Dan for years, and are very pleased to announce his addition to the team,” said Andy Astor, Chief Executive Officer of Nephros. “Dan brings deep experience and knowledge of the microcap life sciences environment, having served as CFO in a microcap...

SAN CLEMENTE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — CareTrust REIT, Inc. (Nasdaq:CTRE) today reported operating results for the quarter ended September 30, 2020, as well as other recent events.For the quarter, CareTrust REIT reported:Net income of $21.6 million and net income per diluted weighted-average common share of $0.23;Normalized FFO of $32.5 million and normalized FFO per diluted weighted-average common share of $0.34;Normalized FAD of $33.9 million and normalized FAD per diluted weighted-average common share of $0.36; andA net debt-to-normalized EBITDA ratio of 3.1x, and a net debt-to-enterprise value of 22.0%, each as of quarter-end.Lengthening the Runway“Our tenants and their outstanding care teams continue to make impressive gains against the global pandemic,” said Greg Stapley, CareTrust’s Chairman and...

TORONTO and MINNEAPOLIS, Nov. 05, 2020 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY) (TSX: CDAY), a global leader in human capital management (HCM), today announced that it has hired Seth Ross as General Manager, Dayforce Wallet and Consumer Services.Dayforce Wallet is an industry-first solution that enables employees to access earned wages on-demand, with no direct fees to employers or employees, by loading earned pay onto their Dayforce Card. It was recently recognized as a “Top HR Product” by Human Resource Executive.Ross, who has deep experience creating embedded financial services products serving both the banked and underbanked communities, will lead the Dayforce Wallet and Consumer Services team, with the mission to expand wallet and financial wellness features, and scale the offering globally.He comes to Ceridian from Green Dot...

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.“We continue to make important progress advancing rezafungin through Phase 3 clinical development. Based on current enrollment trends, we now anticipate top-line data from the ReSTORE trial by the end of 2021, although we continue to monitor the impact of the COVID-19 pandemic on enrollment in our clinical trials,” said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara. “This quarter, we were also pleased to announce the formation of a scientific...

— Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) with resumption of COVID-impacted enrollment and dosing —— Presented promising preclinical data at NACFC from next-generation CF program that leverages advances in mRNA technology —— Reported positive preclinical results from COVID-19 mRNA vaccine program with collaborator Sanofi Pasteur; Phase 1/2 clinical trial now anticipated to begin in first quarter 2021 —LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced financial results for the third quarter ended September 30, 2020 and reviewed...

IRVING, Texas , Nov. 05, 2020 (GLOBE NEWSWIRE) — CorePoint Lodging Inc. (NYSE: CPLG) (“CorePoint” or the “Company”), a pure play select-service hotel owner strategically focused on the midscale and upper-midscale segments, today reported operational and financial results for the third quarter ended September 30, 2020.Third Quarter 2020 and Subsequent HighlightsNet loss of $(8) million, or $(0.14) loss per fully diluted shareComparable RevPAR of $37.35, a decrease of 42.2% from the same period in 2019 with 798 basis points of RevPAR Index market share gainAdjusted EBITDAre of $8 millionAdjusted FFO attributable to common stockholders of $0 millionAll of the Company’s hotels are currently open and operationalHotel room demand was generally consistent during the quarter with comparable occupancy of 52.3%Sold 20 non-core hotels for...

BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020.Recent Clinical Program HighlightsMavacamten for Hypertrophic Cardiomyopathy (HCM)EXPLORER-HCM Data Presented at the European Society of Cardiology 2020 Virtual Congress and Published in The Lancet: Results from MyoKardia’s Phase 3 clinical study of mavacamten for the potential treatment of symptomatic, obstructive HCM demonstrated statistically significant improvements in patient symptoms and cardiac function, as well as reductions in left ventricular outflow tract (LVOT) obstruction. In addition to meeting the primary and all secondary endpoints, mavacamten showed reductions in biomarkers of cardiac wall stress and myocardial injury and was well tolerated, with a safety...

ROUYN-NORANDA, Quebec, Nov. 05, 2020 (GLOBE NEWSWIRE) — Brunswick Resources Inc. (the “Company” or “Brunswick”) (TSX-Venture Exchange: BRU) announces that effective on November 6, 2020, Brunswick Resources Inc. stock’s exchange listing will be transferred from the TSX-V’s to the NEX board as a result of the Company’s failure to meet the Continued Listing Requirements as a Tier 2 issuer on the TSX-V..Brunswick Resources’ trading symbol will change from “BRU” to “BRU.H”. There will be no change in Brunswick Resources’ name, no change in its CUSIP number and no consolidation of capital. As of November 6, 2020, the Company will be subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The NEX board has been designed to provide a forum for the trading of publicly listed companies while...